1)Utsunomiya A, et al. Improved outcome of adult T-cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001; 27(1): 15–20. (3iiiA)

2)Kami M, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukemia/ lymphoma. Br J Haematol. 2003; 120(2): 304–9. (3iiiA)

3)Kato K, et al. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant. 2007; 13(1): 90–9. (3iiiA)

4)Fukushima T, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005; 19(5): 829–34. (3iiiA)

5)Hishizawa M, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010; 116(8): 1369–76. (3iiiA)

6)Ito A, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021; 5(20): 4156–66. (3iiiA)

7)Imaizumi Y, et al. Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study. Cancer Sci. 2020; 111(12): 4567–80. (3iiiA)

8)Yamasaki R, et al. Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma. Leukemia. 2007; 21(6): 1212–7.

9)Inoue Y, et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transplant. 2018; 53(9): 1105–15. (3iiiA)

10)Fuji S, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016; 51(2): 205–11. (3iiiA)

11)Kanda J, et al. Impact of graft-versus-host disease on outcome after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012; 119(9): 2141–8. (3iiiA)

12)Ishida T, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012; 120(8): 1734–41. (3iiiA)

13)Okamura J, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005; 105(10): 4143–5. (2A)

14)Tanosaki R, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T-cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant. 2008; 14(6): 702–8. (3iiiA)

15)Choi I, et al. Long-term outcome after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant. 2011; 46(1): 116–8. (3iiiA)

16)Inoue Y, et al. Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. Bone Marrow Transplant. 2021; 56(12): 2964–74. (3iiiA)

17)Muranushi H, et al. GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2021; 56(1): 155–66. (3iiiA)

18)Fuji S, et al. A decision analysis comparing unrelated bone marrow transplantation and cord blood transplantation in patients with aggressive adult T-cell leukemia-lymphoma. Int J Hematol. 2020; 111(3): 427–33. (3iiiA)

19)Tamaki H, et al. Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med. 2006; 354(16): 1758–9.

20)Eligibility Criteria for Related-donor Hematopoietic Stem Cell Donor (Bone Marrow/peripheral Blood) Enrollment in Donor Accident Insurance (August 2015, Version 2.2), The Japan Society for Hematopoietic Cell Transplantation Donor Committee.

21)Fuji S, et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol. 2016; 34(28): 3426–33. (3iiiA)

CQ4 Is use of cord blood or an HLA-haploidentical donor useful in allogeneic HSCT for aggressive ATL?